To study the protective effect of prostacyclin (PGI2) we increased PGI2 production by infected NRK-52E cells with an adenovirus carrying cyclooxygenase-1 and prostacyclin synthase. PGI2 overexpression protected these cells from gentamicin-induced apoptosis by reducing cleaved caspase-3 and caspase-9, cytochrome c, and decreasing generation of reactive oxygen species. Expression of the nuclear receptor of PGI2, peroxisome proliferator-activated receptor-a (PPARa), was reduced during gentamicin treatment of the cells, while its overexpression significantly inhibited gentamicin-induced apoptosis and the amount of cleaved caspase-3. Transformation with PPARa short interfering RNA abolished the protective effect of PGI2 overproduction in gentamicintreated cells. The PPARa activator docosahexaenoic acid given to gentamicin-treated mice significantly reduced the number of apoptotic cells in renal cortex, but this protective effect was not seen in PPARa knockout mice. Our study suggests that increased endogenous PGI2 production protects renal tubular cells from gentamicin-induced apoptosis through a PPARa-signaling pathway.
Gentamicin is a widely used aminoglycoside antibiotic for the treating Gram-negative bacterial infection, but its clinical use is limited because gentamicin-induced acute renal failure with acute tubular necrosis occurs in about 20% of patients. 1 Although the intravenously administered gentamicin is almost entirely eliminated by the kidney, a small but toxic portion is selectively reabsorbed and accumulated in the proximal tubular cells. 1, 2 Inducing apoptosis is an important cytotoxic mechanism of gentamicin, which has been reported in gentamicin-treated renal proximal tubular cells and mesangial cells. [3] [4] [5] Servais and co-workers 4, 6 reported that the concentration of gentamicin in the 1-to 3-mM range is related to the onset of gentamicin-induced apoptosis. The mitochondrial pathway has been reported to involve in gentamicin-induced apoptosis in LLC-PK1 cells, 6 which induces a major caspase activation to cause apoptosis in mammalian cells. 7 Additionally, reactive oxygen species (ROS) are often responsible for the mitochondria-mediated signaling pathway of apoptosis. A lot of in vivo and in vitro evidence indicates that ROS are important mediators of gentamicin-induced apoptosis. 8 Therefore, the ROS-mediated apoptosis signaling plays a major role in gentamicin-induced cytotoxicity.
Prostacyclin (PGI 2 ), one of the major prostaglandins (PGs), is originated from arachidonic acid by the cyclooxygenase (COX) system coupled to the action of PGI 2 synthase (PGIS).
9 PGI 2 acts on platelets and blood vessels through its specific cell-surface receptor (IP receptor), thereby inhibiting platelet function and dilating blood vessels. 10 Besides, recent reports show that PGs are also the ligands of peroxisome proliferator-activated receptors (PPARs), which belong to a family of ligand-activated transcription factors. 11 The agonists of PGI 2 , cPGI and iloprost, can effectively induce DNA binding and transcriptional activation by PPARa and PPARd, 12 but the same effect did not exist in those experimental conditions with PGI 2 treatment alone, possibly because the chemical instability of this PG precluded it to reach the nuclear target. PGI 2 is also known to inhibit leukocyte functions such as migration and ROS production 13 and inhibit mesangial cell proliferation.
14 Another PGI 2 analogue, beraprost, has been reported to prevent radiocontrast nephropathy in LLC-PK1 cells. 15 These data reveal the protective effect of PGI 2 on certain cell types.
Recently, we selectively augmented PGI 2 production through adenovirus-mediated transfer of genes for COX-1 and PGIS to rat renal tubular cells, and protected cells from the apoptosis induced by adriamycin, an antitumor anthracycline antibiotic. 16 This implies the therapeutic potential of endogenous PGI 2 for nephrosis. Moreover, recent studies have established that the use of fibrates, PPARa ligands, ameliorates ischemia-reperfusion and cisplatin-mediated proximal tubule cell death by prevention of lipotoxicity, inhibition of fatty acid oxidation, and prevention of renal inflammation. [17] [18] [19] [20] Therefore, we hypothesize that PPARa is involved in the protective mechanism of PGI 2 because this PG is a potential activator for PPARa. In this study, we intended to evaluate the protective effect of PGI 2 on gentamicin-induced injury in rat renal tubular cells with the adenovirus-mediated bicistronic COX-1/PGIS transfection, and to investigate PPARa's in vitro and in vivo protective effects.
RESULTS

Ad-COX-1/PGIS transfection protects NRK-52E cells against gentamicin-induced apoptotic injury
To determine the gentamicin-induced apoptosis in rat renal tubular cell NRK-52E, we treated NRK-52E cells with gentamicin and detected them with enzymatic labeling of DNA strand breaks using terminal deoxynucleotidyl transferase-mediated deoxyuridine triphosphate nick end-labeling (TUNEL). With different administration time, the apoptosis cells were markedly increased by treatment with 3 mM of gentamicin for 24 h, and ascended along the administration time ( Figure 1a ). In the dosage test, 2 mM of gentamicin was a minimal requirement to induce significant apoptosis in NRK-52E cells within 24 h (Figure 1b) .
The production of PGI 2 was typically monitored by measurement of 6-keto-prostaglandin F 1a (6-keto-PGF 1a ) because 6-keto-PGF 1a is a stable product of the nonenzymatic hydration of PGI 2 . Compared with the adenoviralhuman phosphoglycerate kinase (Ad-HPGK) control in Figure 2a , Ad-COX-1/PGIS transfection increased PGI 2 levels in a dose-dependent manner. We also examined the protective effect of Ad-COX-1/PGIS with TUNEL staining. Figure 2b shows that Ad-COX-1/PGIS transfection reduced gentamicin-induced apoptosis in a dose-dependent manner. The result of the study also reveals that the endogenous PGI 2 increase caused by Ad-COX-1/PGIS transfection protects rat renal tubular cells from gentamicin-induced apoptosis.
Effect of Ad-COX-1/PGIS transfection on apoptosis signaling induced by gentamicin in NRK-52E cells
To evaluate the mechanism of the protective effect of Ad-COX-1/PGIS transfection on gentamicin-induced apoptosis, the influence of Ad-COX-1/PGIS transfection on the cellular uptake of gentamicin was first monitored. NRK-52E cells were transfected with Ad-COX-1/PGIS or Ad-HPGK at 40 multiplicity of infection (MOI) for 2 days, and then treated with 3 mM of gentamicin. As shown in Figure 3a, there was a basal level of gentamicin in the 0-h groups. This may result from gentamicin adhering to the cell membranes of NRK-52E cells. After gentamicin treatment, the concentration of cytosol gentamicin reached a maximum within 30 min. Compared with Ad-HPGK transfection, Ad-COX-1/PGIS transfection did not influence the concentration of cytosol gentamicin. This result reveals that Ad-COX-1/PGIS transfection did not influence the cellular uptake of gentamicin. We next examined whether Ad-COX-1/PGIS transfection prevents gentamicin-induced ROS formation because ROS generation is involved in gentamicin-induced apoptosis. Ad-COX-1/PGIS-or Ad-HPGK-transfected cells were treated with 3 mM of gentamicin for 24 h. Gentamicin-induced increases in intracellular ROS were revealed by fluorescent intensities of 2 0 ,7 0 -dichlorofluorescein (DCF). As shown in Figure 3b , Ad-COX-1/PGIS transfection significantly inhibited gentamicin-induced ROS formation. On the other hand, Ad-COX-1/PGIS transfection significantly induced the activity of antioxidant enzymes, superoxide dismutase (SOD) and catalase, in NRK-52E cells (Figure 3c and d) . Caspase-dependent signaling plays a major role in apoptotic signaling pathway. 21 We evaluate caspase-3 and caspase-9 activities stimulated by gentamicin by monitoring the quantity of cleaved subtypes of caspase-3 and caspase-9 in NRK-52E cells. Figure 3e indicates that the cleaved subtypes of both caspase-3 and caspase-9 were significantly elevated in the cells treated with gentamicin. Compared with Ad-HPGK transfection, Ad-COX-1/PGIS transfection significantly reduced the quantity of cleaved subtypes of both caspase-3 and caspase-9 in gentamicin-treated NRK-52E cells. The increase of cleaved caspase-9 is associated with mitochondriamediated signaling pathway in apoptosis.
We also monitored the influence of Ad-COX-1/PGIS transfection on two mitochondria-associated signaling molecules, cytochrome c and Bcl-x L . Figure 3e shows that in the gentamicin-alone treatment group, cytosol cytochrome c was increased significantly and the expression of Bcl-x L was reduced, but the variations of cytosol cytochrome c and Bcl-x L were inhibited by Ad-COX-1/PGIS transfection.
Ad-COX-1/PGIS transfection induced the translocation of PPARa
PPARa, a potential PGI 2 receptor, has been reported inhibiting cisplatin-mediated proximal tubule cell death. 17 To evaluate the possibility that PPARa is involved in the protective mechanism of PGI 2 , we monitored the mRNA level of PPARa in NRK-52E cells using real-time polymerase chain reaction. Figure 4a shows that gentamicin significantly reduced the transcription level of PPARa compared with non-treated control cells. Neither Ad-HPGK nor Ad-COX-1/ PGIS obviously influences the mRNA level of PPARa in NRK-52E cells with or without gentamicin treatment.
The quantity of total PPARa protein in Ad-COX-1/PGIStransfected cells was also similar to that in Ad-HPGKtransfected cells (data not shown). Figure 4b shows that the nuclear PPARa protein in NRK-52E cells was significantly increased by the 12-h transfection of Ad-COX-1/PGIS, and ascended along the transfection time. This result reveals that PGI 2 generated by Ad-COX-1/PGIS transfection induces the translocation of PPARa.
PPARa plays a crucial role in the protective mechanism of PGI 2 generated by Ad-COX-1/PGIS transfection in NRK-52E cells
Inducing the translocation of PPARa implies that PPARa plays a role in the protective mechanism of PGI 2 . We first overexpressed PPARa fusion protein in NRK-52E cells to evaluate the protective effect of PPARa against gentamicininduced apoptosis. Figure 5a shows that Flag-PPARa construction overexpressed the fusion protein in NRK-52E cells compared with controls or vector transformants. Figure  5b indicates that PPARa overexpression significantly reduced the quantity of cleaved caspase-3 in gentamicin-treated NRK-52E cells. In TUNEL assays, PPARa overexpression significantly reduced gentamicin-induced apoptosis in NRK-52E cells ( Figure 5c ). Figure 6a demonstrates that PPARa overexpression inhibited the gentamicin-induced ROS, and Figure  6b and c show that the activity of catalase and SOD was also increased in Flag-PPARa-transformed NRK-52E cells.
We applied gene knockdown to analyze the relationship between PPARa and the protective effect of PGI 2 . Figure 7a shows that NRK-52E cells were transfected with the PPARa short interfering RNA (siRNA), and the PPARa transcription level was obviously reduced. As shown in Figure 7b and c, PPARa siRNA did not affect gentamicin-induced apoptosis and cleaved caspase-3, but reduced the inhibition of Ad-COX-1/PGIS transfection on the gentamicin-induced apoptosis and cleaved caspase-3.
The protective effect of PPARa on gentamicin-induced apoptosis in vivo
The protective effect of PPARa on gentamicin-induced apoptosis was further proven with docosahexaenoic acid in vivo. Docosahexaenoic acid (DHA), a long-chain fatty acid, is known as one of the PPARa activators. 22 Normal and PPARa-deficient mice were treated with gentamicin (20 mg kg À1 day
À1
) or saline as controls; the experimental groups were treated with DHA (200 mg kg À1 day
) in addition. At the end of the treatment period (7 days), the renal function of experimental mice was monitored by measuring the concentration of blood urea nitrogen and serum creatinine. Figure 8a and c show that the concentrations of blood urea nitrogen and serum creatinine were not influenced by DHA treatment alone, but elevated in gentamicin-treated groups, and that this gentamicin-induced elevation was significantly inhibited by DHA treatment. The influence of DHA treatment on gentamicin uptake in mouse kidneys was also monitored at 120 min after the single injection of gentamicin without or with DHA ( Figure 8b ). There was no significant difference between the gentamicin quantity in mouse kidneys with and without DHA treatment. This result reveals that DHA did not influence the gentamicin uptake in mouse kidneys. In addition, morphology study of tubular injury in mouse kidneys was carried out with hematoxylin and eosin staining. In normal mice, gentamicin caused swollen and vacuolated epithelial cell degeneration with tubular dilatation and intraluminal cell debris, which was reduced by DHA treatment (Figure 8d ). Compared with normal mice, gentamicin caused more serious degeneration and necrosis of epithelial cells, with granular and proteinaceous casts in tubular lumen in PPARa-deficient mice irrespective of DHA treatment (Figure 8d ).
To analyze gentamicin-induced apoptosis, we next examined kidney sections after having detected DNA fragmentations with the in situ TUNEL assay. As shown in Figure 8e , total nuclei in kidney sections were shown as bright spots stained with 4 0 ,6-diamidino-2-phenyindole. The scattered and bright nuclei stained by TUNEL staining could easily be detected over the entire cortex from gentamicin-treated animals, yet they were rarely detected in the specimens of the controls and gentamicin-DHA-treated animals ( Figure 8e ). Most of the TUNEL-labeled nuclei were seen in proximal tubule epithelium. This result reveals that the PPARa activator DHA inhibits the gentamicin-induced cell apoptosis in the renal cortex in mice. Furthermore, the protective effect of DHA on gentamicin-induced apoptosis was also evaluated in PPARa-deficient mice. In PPARa-deficient mice, TUNEL-labeled nuclei detected in the cortex from gentamicin-treated animals were much more than that in normal mice (Figure 8f) . Besides, the gentamicin-induced apoptosis was rarely reduced by DHA treatment in PPARa-deficient mice (Figure 8f ).
DISCUSSION
The result in our previous study has shown that the cotransfection of COX-1 and PGIS selectively augments PGI 2 synthesis in NRK-52E cells as well as protects cells from adriamycin injury. 16 The results of this study indicate that Adv-COX-1/PGIS-induced PGI 2 augmentation is also effective in reducing apoptotic death caused by gentamicin (Figure 2) . We monitored the apoptotic signals associated with gentamicin, such as increase of cleaved caspase-3, caspase-9, and cytochrome c release, and decrease in Bcl-x L . These apoptotic signals present in gentamicin-treated NRK-52E cells were reversed by Ad-COX-1/PGIS transfection (Figure 3e) . Besides, gentamicin-induced ROS generation was also inhibited by Ad-COX-1/PGIS transfection (Figure 3b ). This inhibition should be associated with the elevation of the activity of catalase and SOD caused by Ad-COX-1/PGIS transfection (Figure 3c and d) . Since ROS are an important apoptotic stimulator, the inhibition of ROS generation is supposed to be one of protective mechanisms of PGI 2 .
PPARa is supposed to be a potential nuclear receptor for PGI 2 .
11,12 As shown in Figure 4a , the PPARa mRNA level was found to be significantly inhibited in gentamicin-treated NRK-52E cells, and not influenced by Ad-COX-1/PGIS transfection, but the finding of our study showed that Ad-COX-1/PGIS transfection activated PPARa, resulting PPARa translocation (Figure 4b ). Gentamicin-induced apoptosis was significantly reduced after having overexpressed PPARa in NRK-52E cells ( Figure 5 ). Besides, gentamicin-induced apoptosis was more serious in renal tubular cells in PPARa-deficient mice compared with that in normal mice ( Figure 8 ). Based on the finding of the study, we suggest that PPARa is associated with the inhibition of gentamicininduced apoptosis in renal tubular cells. Since some PPAR-a ligands, such as certain fatty acids, originally are present in cytosol, the overexpression of PPARa in NRK-52E cells is supposed to increase the active form of PPARa. As shown in Figure 6 , the PPARa ligand DHA can also protect renal tubular cells from gentamicin-induced apoptosis in normal mice. Therefore, the protective function of PPARa on gentamicin-induced apoptosis should result from the activation of PPARa. Additionally, endogenous PGI 2 augmentation caused by Ad-COX-1/PGIS transfection lost the protective effect in PPARa siRNA-transfected cells (Figure 7 ). DHA also lost protective effect on gentamicin-induced apoptosis in renal tubular cells in vivo (Figure 8 ). These results are direct evidences to prove that the activation of PPARa is crucial for the protective function of PGI 2 on gentamicin-induced apoptosis in renal tubular cells. But the detailed protective mechanism of PPARa is not clear yet. Our results revealed that the activation of PPARa did not influence gentamicin uptake in vitro and in vivo (Figures 3a and 8b ). Similar to Ad-COX-1/PGIS transfection, overexpressing PPARa could activate catalase and SOD, and inhibit gentamicin-induced ROS generation in NRK-52E cells ( Figure 6 ). We suggest that the PGI 2 protective effect on gentamicin-induced apoptosis is due to PPARa's inhibiting ROS generation in renal tubular cells. Although PGI 2 is supposed to be the ligand of PPARs, the connection between endogenous PGI 2 and the activation of PPARa is still not conclusive. 11 The data in this study prove that Adv-COX-1/PGIS transfection induces the activation of PPARa in NRK-52E cells. Previous studies have shown that Adv-COX-1/PGIS transfection is effective in augmenting COX-1 and PGIS expression, and increases PGI 2 without overproduction of other prostanoids in endothelial, cerebral, and rat renal tubular cells. 16, 23, 24 We speculate that this endogenous augmented PGI 2 can interact with and activate PPARa without the interference of other PGs. Through PPARa-signaling pathway, PGI 2 can negate gentamicininduced apoptosis; but several recent independent reports show that endogenously produced PGI 2 indeed activates PPAR-d in vivo, [25] [26] [27] and then uses PPARd to modulate apoptotic process as well. 11, 28 Differing in results of our study, these data in the literature indicate that PGI 2 plays a proapoptotic role. Besides different kinds of experimental cells, the data about the proapoptotic effect of PGI 2 are often obtained with COX-2/PGIS cotransfection but not Ad-COX-1/PGIS transfection applied in this study. The difference between the physiological effects of COX-1 and COX-2 may cause the PGI 2 experimental diversity. Possibly, PGI 2 has both proapoptotic and antiapoptotic effects through activating PPARd and PPARa, respectively. The mechanism of how both opposite effects of PGI 2 are regulated is still unknown.
In summary, Adv-COX-1/PGIS transfection can increase the endogenous PGI 2 production to inhibit gentamicininduced ROS generation, to enhance Bcl-x L expression, to reduce cytochrome c release and the activity of caspases, and eventually to protect NRK-52E cells from gentamicin-induced apoptosis. The findings of our present study also show that PGI 2 could protect the injury due to PPARa activation. With gentamicin treatment, the expression level of PPARa was significantly reduced in NRK-52E cells, resulting in apoptotic signals to negate PPARa's protective effect. Overexpressing PPARa or transfecting Ad-COX-1/PGIS to activate PPARa in cultured cells can inhibit gentamicin-induced apoptosis extensively. In mice, the PPARa ligand DHA also protected renal tubular cells from gentamicin-induced apoptosis, but not in PPARa-deficient animals. Based on these findings, we suggest that the activation of PPARa can improve the gentamicin-induced injury in kidney.
MATERIALS AND METHODS Reagents
Dulbecco's modified Eagle's medium, fetal calf serum, and tissue culture reagents from Invitrogen Corporation (Carlsbad, CA, USA). All other chemicals of reagent grade were obtained from Sigma (St Louis, MO, USA). Antibodies used in this research were purchased from BD Biosciences (San Jose, CA, USA) and Santa Cruz Biotechnology (Santa Cruz, CA, USA).
Cell culture
We purchased rat proximal renal tubular cells (NRK-52E) from Bioresource Collection and Research Center (Hsinchu, Taiwan), and cultured them in Dulbecco's modified Eagle's medium supplemented with antibiotic/antifungal solution and 10% fetal calf serum. They were grown until the monolayer became confluent. The medium for the cultured cells was then changed to the serum-free medium and the cells were incubated overnight before the experiment.
TUNEL staining
We detected gentamicin-mediated apoptosis in NRK-52E cells by enzymatically labeling DNA strand breaks using TUNEL stain. As described previously, 16 TUNEL staining was performed with a Cell Death Detection kit (Roche, Mannheim, Germany). To reveal total nuclei, we stained the same slides with 4 0 ,6-diamidino-2-phenyindole (1 mg ml
À1
) in phosphate-buffered saline plus 0.5% 1,4-diazabicyclo [2,2,2]octane. Additionally, we also processed kidney slides with an ApopTag Fluorescein in situ apoptosis detection kit (Chemicon International Inc., Temecula, CA, USA) according to the manufacturer's instructions. Briefly, kidney-tissue slides were incubated with the reaction mixture containing terminal deoxynucleotidyl transferase and digoxigenin-conjugated dUTP for 1 h at 371C, and mounted with mounting solution containing 4 0 ,6-diamidino-2-phenyindole and observed with fluorescent microscope.
Preparing replication-defective recombinant adenoviral vectors
We constructed the replication-defective recombinant adenoviral vector with two separate HPGK promoters (bicistronic) to drive COX-1 and PGIS (Ad-COX-1/PGIS), and an HPGK alone to serve as control (Ad-HPGK) as previously described. 23 Replication-defective recombinant adenoviral vectors were generated by homologous recombination and amplified in 293 cells as described previously. 23 Measuring PGI2 by enzyme immunoassay Cells were sonicated in 1 ml of ice-cold buffer (0.05 M Tris at pH 7.0, 0.1 M NaCl, and 0.02 M EDTA) and centrifuged at 55 000 g for 1 h. The supernatant was analyzed using 6-keto-PGF 1 enzyme-linked immunosorbent assay kits from R&D Systems Inc. (Minneapolis, MN, USA) for PGI 2 detection.
Determining cellular uptake of gentamicin
We cultured the NRK-52E cells in 6-cm plates with 3 mM gentamicin for different time periods with Ad-COX-1/PGIS or Ad-HPGK transfection at 40 MOI for 2 days, washed them three times with phosphate-buffered saline buffer, and then lysed them with immunoprecipitation assay buffer. The 0-h group cells were washed immediately after gentamicin treatment. The concentration of gentamicin in each sample was detected using Gentamicin EIA kits according to instructions provided by the manufacturers (EuroDiagnostica BV, Arnhem, The Netherlands).
Detecting intracellular ROS
Before the chemical treatment, we incubated NRK-52E cells in culture medium containing a fluorescent dye, DCF of 30 mM, for 30 min to establish a stable intracellular level of the probe. Subsequently, the cells were washed with phosphate-buffered saline, removed from Petri dishes by scraping, and measured for DCF fluorescence intensity using fluorescence spectrophotometer with excitation and emission wavelengths at 475 and 525 nm, respectively. The cell number in each sample was counted and utilized to normalize the fluorescence intensity of DCF. We also detected the activity of catalase and SOD in NRK-52E cells by using Catalase Assay kit and Superoxide Dismutase Assay kit according to instructions provided by the manufacturers (Cayman Chemical Company, Ann Arbor, MI, USA).
Western blot analysis
A total of 30 mg of NRK-52E lysate proteins were applied to each lane and analyzed by western blotting. The antibodies to PPARa, Flag, caspase-3, caspase-9, cytochrome c, Bcl-x L , and glyceraldehyde-3-phosphate dehydrogenase were diluted to 1:1000 for assay. Peroxidase-conjugated anti-rabbit or anti-goat IgG was used as the second antibody to detect primary antibodies by enhanced chemiluminescence (Amersham Biosciences Corp., Piscataway, NJ, USA). The preparation of nuclear protein extracts has been described previously. 16 RNA extraction and the real-time polymerase chain reaction analysis Total RNA was extracted from NRK52E cells using the TRIzol method according to the protocol recommended by the manufacturer (Invitrogen Corporation).
PPARa mRNAs were quantified using SYBR Green Master Mix (QIAGEN GmbH, Hilden, Germany) with specific primers in a GeneAmp ABI prism 7000 (Applied Biosystems, Foster City, CA, USA). The primers for PPARa were as follows:
0 . Calibrated and non-template controls were included in each assay. Each sample was run in triplicate. SYBR Green dye intensity was analyzed using the ABI prism 7000 SDS software (Applied Biosystems). All results were normalized to glyceraldehyde-3-phosphate dehydrogenase. All quantifications were performed in triplicate samples for three separate experiments.
Immunoprecipitation NRK-52E cells were transfected with Ad-COX-1/PGIS or Ad-HPGK at 40 MOI for different periods. The cells were lysed at 41C in lysis buffer (50 mM Tris, pH 7.5, 1% Nonidet P-40, 0.5% sodium deoxycholate, 150 mM NaCl, protease inhibitors). PPARa was collected by using the immunoprecipitation kit (Roche Molecular Biochemicals, Mannheim, Germany) with PPARa antibody (sc-9000; Santa Cruz Biotechnology), following the manufacturer's instructions.
PPARa cDNA and siRNA transfection The PPARa cDNA was kindly gifted by Dr SK Shyue (Institute of Biomedical Sciences, Academia Sinica, Taipei, Taiwan), and the PPARa siRNA (catalog number M-005714-00) was purchased from Panomics Inc. (Fremont, CA, USA). Cells with or without Ad-COX-1/PGIS transfection were grown to 70% confluence, and FlagPPARa construct or PPARa siRNA and their respective control oligonucleotides were transfected using the Lipofectamine reagent according to the manufacturer's instructions (Invitrogen, Carlsbad, CA, USA).
Animals and treatments
Male BALB/c mice weighting 20-25 g and aged 8 weeks were obtained from Animal Center, Taiwan University, Taipei, Taiwan. The PPARa-deficient mice were purchased from Charles River Laboratories International Inc. (Wilmington, MA, USA). We housed animals in a central facility submitted them to a 12-h light-dark cycle, and provided them with regular rat chow and tap water. The experimental group animals (n ¼ 6) for gentamicin treatment received to intraperitoneal injection with gentamicin (20 mg kg À1 day À1 ) for 7 days. The animals (n ¼ 6) for gentamicin and DHA treatment received by intraperitoneal injection DHA (200 mg kg À1 day À1 ) 30 min before the gentamicin treatment each time. The control group rats received a continuous infusion of 0.9% (w/v) saline throughout the gentamicin treatment period. Treated and control mice were killed 24 h after the last drug injection and blood samples were collected from the stump for the measurement of serum creatinine and blood urea nitrogen. Both the kidneys were harvested by laparotomy and the renal cortex tissue was snap-frozen in dry ice and stored at À801C until in situ TUNEL assays. For histological analysis, the harvested kidneys were fixed in 10% formalin and embedded in paraffin, and sectioned at 4-mm thickness, then stained with hematoxylin and eosin. In mouse gentamicin uptake study, kidneys were excised at 120 min after the single administration into mice. The tissues were weighed and homogenized with phosphate-buffered saline buffer. The concentration of gentamicin in each sample was detected using Gentamicin EIA kits according to instructions provided by the manufacturers (Euro-Diagnostica BV).
Statistical analysis
Data were presented as the mean ± standard deviation (s.d.), and groups were compared using analysis of variance.
